This is a preview of subscription content, log in via an institution to check access.
Reference
Asseburg C, et al. Cost-Effectiveness and Budget Impact of Certolizumab Pegol Against the Current Mix of Anti-Tnf Treatments in an Outcomes-Based Risk-Sharing Scheme in Finland. 14th Annual Congress of the European League Against Rheumatism : abstr. FRI0184, 12 Jun 2013.
Rights and permissions
About this article
Cite this article
Certolizumab pegol improves RA outcomes, saves costs. PharmacoEcon Outcomes News 683, 9 (2013). https://doi.org/10.1007/s40274-013-0581-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0581-5